Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate

Galectin Therapeutics (NASDAQ: GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from the same period last year.